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Purpose of the study
There is a clinical need for antiretroviral therapy (ART)
regimens that simplify dosing and make adherence easier
for specific patient groups such as former intravenous
drug users (IVDU) receiving opiate substitution. Availa-
bility of tenofovir DF (TDF) and other once-daily (OD)
agents could offer a viable OD regimen. The 3OD study
was designed to evaluate the use of OD HAART in IVDU
patients.
Methods
3OD was a single-arm, multicentre, 48-weeks trial to
assess efficacy, tolerability and adherence to a OD TDF-
containing HAART regimen in former IVDU patients
receiving opiate substitution. Of 67 patients enrolled, 27
were antiretroviral treatment naïve, 10 were virologically
suppressed (<400 copies/mL), and 30 were re-starting
HAART without prior virological failure. Opiate substitu-
tion was adjusted according to subject symptoms of opi-
ate overdosing or withdrawal. Various methods were used
to assess adherence: besides pill count, patients were
asked to fill in a MASRI (Medication Adherence Self-
Report Inventory) questionnaire and an electronic log pad
diary. Calculation of adherence by pill count assumed
that unreturned pills had been taken by the subjects.
Summary of results
Overall, 55% (n = 37, ITT, M = F) of patients had viral load
<400 copies/mL at week 48. Using an ITT, M = E analysis,
90% (37/41) of patients reached undetectable VL (<400
copies/mL), 56% (23/41 patients) had plasma HIV-1 RNA
concentrations <50 copies/mL at week 48. Only 30
patients (45%) completed the full study and the follow-
up period. In 51% of patients, TDF adherence was >100%
using pill count. MASRI showed adherence rates of 80–
100% in 83–85% of patients; however, 15 patients never
entered any data. Diary data were entered by 57 patients;
diary data were entered for fewer days than patients
received treatment (mean difference 113 days, calculated
from treatment start and stop dates).
Conclusion
TDF in combination with other OD antiretrovirals in
former IVDU patients showed comparable efficacy to that
seen in the average HIV-1 infected population. However,
measurement of adherence to self-administered HAART
via pill count, MASRI or diary may be misleading in this
population.
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